Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

NCT06258174
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

NCT02464878
View directory record Official record
Conditions
Kidney Transplant, Type 1 Diabetes
Interventions
Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants

NCT01758913
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Ibuprofen
Drug
Lead sponsor
Taipei Medical University Hospital
Other
Eligibility
Up to 6 Months
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06349408
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
IBI3001
Drug
Lead sponsor
Fortvita Biologics (USA)Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • East Brunswick, New Jersey • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

NCT02563925
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed therapy, Durvalumab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Study of GemOx and Vandetanib in Advanced Solid Malignancy

NCT00660725
View directory record Official record
Conditions
Advanced Incurable Solid Malignancy
Interventions
Vandetanib, Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

NCT01846481
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions
RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 24, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

NCT01207765
View directory record Official record
Conditions
Multiple Myeloma
Interventions
indium-111-ibritumomab tiuxetan, 90Y Zevalin
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 24, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

Pilot Study of Dietary Modification of Appetite Set Point in Obesity

NCT00726271
View directory record Official record
Conditions
Obesity
Interventions
light olive oil, fish oil capsules, flax seed oil capsules
Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Early Phase 1 Interventional

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

NCT02621944
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Melatonin, Magnetic Resonance Imaging, Pharmacokinetics, Neurological Outcome Assessment
Drug · Other · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
Up to 6 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Not applicable Interventional

Barotrauma in Hyperbaric Oxygen Therapy

NCT05697328
View directory record Official record
Conditions
Barotrauma
Interventions
Pseudoephedrine Pill, Placebo
Drug
Lead sponsor
John Muir Health
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

NCT06586671
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

NCT00402025
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Talimogene Laherparepvec
Biological
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Orange, California • San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 24, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia

NCT01309659
View directory record Official record
Conditions
Anemia, Unexplained Anemia (UAE)
Interventions
iron sucrose
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Window of Opportunity in Preserving Laryngeal Function Trial

NCT07423078
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

NCT06207123
View directory record Official record
Conditions
Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

NCT00957268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 24, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Iadademstat + SBRT With Atezo in ES-SCLC

NCT07113691
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Iadademstat, Atezolizumab, SBRT
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease

NCT03356990
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Resistant Starch
Dietary Supplement
Lead sponsor
University of Arkansas
Other
Eligibility
5 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 24, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

NCT03901313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 24, 2026, 10:53 AM EDT